Concepts (160)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anti-Bacterial Agents | 14 | 2003 | 1026 | 1.010 |
Why?
|
| Microbial Sensitivity Tests | 15 | 2003 | 226 | 0.810 |
Why?
|
| Ceftazidime | 6 | 2003 | 12 | 0.540 |
Why?
|
| Cephalosporins | 9 | 2000 | 59 | 0.490 |
Why?
|
| Fluoroquinolones | 4 | 2003 | 49 | 0.470 |
Why?
|
| Pseudomonas aeruginosa | 8 | 2003 | 133 | 0.460 |
Why?
|
| Imipenem | 3 | 2001 | 9 | 0.430 |
Why?
|
| Streptococcus pneumoniae | 2 | 2002 | 32 | 0.400 |
Why?
|
| Drug Therapy, Combination | 4 | 2002 | 649 | 0.380 |
Why?
|
| Thienamycins | 2 | 2001 | 4 | 0.330 |
Why?
|
| Bacteria | 2 | 2001 | 193 | 0.300 |
Why?
|
| Bacteroides fragilis | 3 | 2001 | 20 | 0.300 |
Why?
|
| Ofloxacin | 2 | 2003 | 15 | 0.280 |
Why?
|
| Levofloxacin | 2 | 2003 | 23 | 0.270 |
Why?
|
| Anti-Infective Agents | 3 | 2002 | 166 | 0.270 |
Why?
|
| Drug Synergism | 5 | 2002 | 260 | 0.240 |
Why?
|
| Drug Resistance, Bacterial | 2 | 2002 | 98 | 0.240 |
Why?
|
| Aza Compounds | 1 | 2003 | 7 | 0.220 |
Why?
|
| Quinolines | 1 | 2003 | 48 | 0.220 |
Why?
|
| Gram-Negative Bacteria | 2 | 2000 | 55 | 0.220 |
Why?
|
| Escherichia coli | 3 | 2001 | 368 | 0.210 |
Why?
|
| Staphylococcus aureus | 2 | 2001 | 175 | 0.200 |
Why?
|
| Models, Biological | 5 | 2003 | 981 | 0.200 |
Why?
|
| Bacterial Infections | 2 | 2001 | 163 | 0.190 |
Why?
|
| Staphylococcus | 1 | 2000 | 29 | 0.180 |
Why?
|
| Bronchial Diseases | 1 | 1999 | 9 | 0.170 |
Why?
|
| Kidney | 2 | 2003 | 945 | 0.160 |
Why?
|
| Cefotaxime | 3 | 1991 | 7 | 0.160 |
Why?
|
| Respiratory Tract Infections | 1 | 1999 | 91 | 0.160 |
Why?
|
| Cystic Fibrosis | 2 | 1999 | 283 | 0.150 |
Why?
|
| Cephamycins | 2 | 1993 | 10 | 0.130 |
Why?
|
| Drug Stability | 4 | 2001 | 71 | 0.100 |
Why?
|
| Penicillins | 2 | 2002 | 32 | 0.100 |
Why?
|
| Infusions, Intravenous | 2 | 2003 | 334 | 0.090 |
Why?
|
| Dose-Response Relationship, Drug | 4 | 2003 | 1745 | 0.090 |
Why?
|
| Burns | 3 | 1999 | 83 | 0.090 |
Why?
|
| Ciprofloxacin | 2 | 2002 | 30 | 0.090 |
Why?
|
| Hysterectomy | 1 | 1988 | 64 | 0.080 |
Why?
|
| Area Under Curve | 3 | 2003 | 238 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2003 | 1342 | 0.070 |
Why?
|
| Tobramycin | 3 | 2000 | 38 | 0.070 |
Why?
|
| Humans | 24 | 2003 | 68618 | 0.070 |
Why?
|
| Kidney Function Tests | 2 | 2003 | 114 | 0.070 |
Why?
|
| Drug Resistance, Microbial | 2 | 1999 | 70 | 0.060 |
Why?
|
| Adult | 13 | 2002 | 21403 | 0.060 |
Why?
|
| Costs and Cost Analysis | 2 | 2003 | 193 | 0.060 |
Why?
|
| Ceftriaxone | 2 | 2002 | 32 | 0.060 |
Why?
|
| Penicillin Resistance | 1 | 2002 | 12 | 0.050 |
Why?
|
| Acinetobacter baumannii | 1 | 2002 | 22 | 0.050 |
Why?
|
| Azithromycin | 1 | 2002 | 13 | 0.050 |
Why?
|
| Administration, Oral | 1 | 2003 | 411 | 0.050 |
Why?
|
| Surface Properties | 1 | 2003 | 363 | 0.050 |
Why?
|
| Pneumococcal Infections | 1 | 2002 | 30 | 0.050 |
Why?
|
| Drug Administration Schedule | 1 | 2003 | 567 | 0.050 |
Why?
|
| Macrolides | 1 | 2002 | 48 | 0.050 |
Why?
|
| Metabolic Clearance Rate | 1 | 2001 | 48 | 0.050 |
Why?
|
| Drug Evaluation | 1 | 2001 | 47 | 0.050 |
Why?
|
| Female | 13 | 2003 | 38074 | 0.050 |
Why?
|
| Respiratory Tract Diseases | 1 | 2002 | 43 | 0.050 |
Why?
|
| Male | 14 | 2003 | 37321 | 0.050 |
Why?
|
| Acinetobacter | 1 | 2000 | 3 | 0.050 |
Why?
|
| Acinetobacter Infections | 1 | 2000 | 5 | 0.050 |
Why?
|
| Tourniquets | 2 | 1990 | 18 | 0.050 |
Why?
|
| Cefazolin | 2 | 1990 | 19 | 0.050 |
Why?
|
| Half-Life | 4 | 1999 | 96 | 0.050 |
Why?
|
| Knee Prosthesis | 2 | 1990 | 64 | 0.040 |
Why?
|
| Patient Care | 1 | 2000 | 61 | 0.040 |
Why?
|
| Kidney Diseases | 1 | 2002 | 307 | 0.040 |
Why?
|
| Respiratory Function Tests | 1 | 1999 | 123 | 0.040 |
Why?
|
| Gram-Negative Bacterial Infections | 1 | 1999 | 62 | 0.040 |
Why?
|
| Cross-Over Studies | 1 | 1999 | 260 | 0.040 |
Why?
|
| Carrier Proteins | 1 | 2001 | 597 | 0.040 |
Why?
|
| Time Factors | 3 | 2003 | 4655 | 0.040 |
Why?
|
| Intensive Care Units | 1 | 2000 | 344 | 0.040 |
Why?
|
| Hospitals | 1 | 2000 | 265 | 0.040 |
Why?
|
| Randomized Controlled Trials as Topic | 1 | 2001 | 931 | 0.040 |
Why?
|
| Adolescent | 6 | 2002 | 8912 | 0.040 |
Why?
|
| Piperacillin | 2 | 2000 | 6 | 0.040 |
Why?
|
| Teicoplanin | 1 | 1996 | 5 | 0.040 |
Why?
|
| Dialysis Solutions | 1 | 1996 | 5 | 0.040 |
Why?
|
| Enterobacter cloacae | 1 | 1996 | 4 | 0.040 |
Why?
|
| Blood Proteins | 2 | 2002 | 94 | 0.030 |
Why?
|
| Mathematics | 1 | 1996 | 83 | 0.030 |
Why?
|
| Middle Aged | 9 | 2002 | 21147 | 0.030 |
Why?
|
| Insurance, Health, Reimbursement | 2 | 1994 | 47 | 0.030 |
Why?
|
| Burn Units | 1 | 1994 | 14 | 0.030 |
Why?
|
| Aged | 6 | 2002 | 14862 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 1994 | 1040 | 0.030 |
Why?
|
| Bone and Bones | 2 | 1990 | 145 | 0.030 |
Why?
|
| Orosomucoid | 1 | 1992 | 5 | 0.030 |
Why?
|
| Clindamycin | 1 | 1992 | 25 | 0.030 |
Why?
|
| Wounds, Penetrating | 1 | 1992 | 45 | 0.020 |
Why?
|
| United States | 2 | 2002 | 7367 | 0.020 |
Why?
|
| Bacteria, Anaerobic | 1 | 1991 | 15 | 0.020 |
Why?
|
| Abdominal Injuries | 1 | 1992 | 60 | 0.020 |
Why?
|
| Chromatography, High Pressure Liquid | 3 | 1999 | 381 | 0.020 |
Why?
|
| Prospective Studies | 1 | 1999 | 3705 | 0.020 |
Why?
|
| Child | 1 | 2002 | 6405 | 0.020 |
Why?
|
| Aztreonam | 1 | 1991 | 6 | 0.020 |
Why?
|
| Quality Control | 1 | 1991 | 81 | 0.020 |
Why?
|
| Creatinine | 2 | 2002 | 243 | 0.020 |
Why?
|
| Regression Analysis | 2 | 1994 | 737 | 0.020 |
Why?
|
| Meningitis, Listeria | 1 | 1990 | 1 | 0.020 |
Why?
|
| Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 1990 | 22 | 0.020 |
Why?
|
| Connective Tissue | 1 | 1990 | 61 | 0.020 |
Why?
|
| Hot Temperature | 1 | 1990 | 152 | 0.020 |
Why?
|
| Health Care Costs | 1 | 1992 | 346 | 0.020 |
Why?
|
| Protein Binding | 3 | 2002 | 1027 | 0.020 |
Why?
|
| Hysterectomy, Vaginal | 1 | 1988 | 4 | 0.020 |
Why?
|
| Proteus vulgaris | 1 | 1987 | 1 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 1 | 1991 | 365 | 0.020 |
Why?
|
| Uterus | 1 | 1988 | 77 | 0.020 |
Why?
|
| Injections, Intravenous | 1 | 1988 | 215 | 0.020 |
Why?
|
| Drug Utilization | 2 | 1999 | 119 | 0.020 |
Why?
|
| Animals | 1 | 2001 | 20881 | 0.010 |
Why?
|
| Lactams | 1 | 2002 | 4 | 0.010 |
Why?
|
| Biological Availability | 1 | 2002 | 79 | 0.010 |
Why?
|
| Reference Standards | 1 | 2002 | 115 | 0.010 |
Why?
|
| Guidelines as Topic | 1 | 2002 | 123 | 0.010 |
Why?
|
| Naphthyridines | 1 | 2000 | 20 | 0.010 |
Why?
|
| Spectrophotometry, Ultraviolet | 1 | 1999 | 79 | 0.010 |
Why?
|
| Antibiotic Prophylaxis | 1 | 1999 | 62 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2002 | 706 | 0.010 |
Why?
|
| Treatment Failure | 1 | 1999 | 216 | 0.010 |
Why?
|
| Linear Models | 1 | 1999 | 521 | 0.010 |
Why?
|
| Drug Storage | 1 | 1996 | 16 | 0.010 |
Why?
|
| Chemistry, Pharmaceutical | 1 | 1996 | 35 | 0.010 |
Why?
|
| Peritoneal Dialysis | 1 | 1996 | 30 | 0.010 |
Why?
|
| Drug Combinations | 1 | 1996 | 304 | 0.010 |
Why?
|
| Temperature | 1 | 1996 | 341 | 0.010 |
Why?
|
| Reproducibility of Results | 1 | 2000 | 2077 | 0.010 |
Why?
|
| Infusions, Parenteral | 1 | 1994 | 47 | 0.010 |
Why?
|
| Diagnosis-Related Groups | 1 | 1994 | 28 | 0.010 |
Why?
|
| Outliers, DRG | 1 | 1992 | 1 | 0.010 |
Why?
|
| Hospital Bed Capacity, 500 and over | 1 | 1992 | 14 | 0.010 |
Why?
|
| Chromatography, Gas | 1 | 1992 | 31 | 0.010 |
Why?
|
| Ultrafiltration | 1 | 1992 | 35 | 0.010 |
Why?
|
| Cefotetan | 1 | 1991 | 3 | 0.010 |
Why?
|
| Ceftizoxime | 1 | 1991 | 3 | 0.010 |
Why?
|
| Medicare | 1 | 1994 | 319 | 0.010 |
Why?
|
| Cefoxitin | 1 | 1991 | 20 | 0.010 |
Why?
|
| Drug Costs | 1 | 1992 | 87 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 1991 | 137 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 1994 | 7277 | 0.010 |
Why?
|
| Drug Interactions | 1 | 1991 | 289 | 0.010 |
Why?
|
| Pseudomonas Infections | 1 | 1991 | 83 | 0.010 |
Why?
|
| Aged, 80 and over | 1 | 1999 | 4848 | 0.010 |
Why?
|
| Ampicillin Resistance | 1 | 1990 | 2 | 0.010 |
Why?
|
| Ampicillin | 1 | 1990 | 17 | 0.010 |
Why?
|
| Listeria monocytogenes | 1 | 1990 | 15 | 0.010 |
Why?
|
| Culture Media | 1 | 1990 | 155 | 0.010 |
Why?
|
| Gentamicins | 1 | 1990 | 68 | 0.010 |
Why?
|
| Infection Control | 1 | 1990 | 101 | 0.010 |
Why?
|
| Tissue Distribution | 1 | 1990 | 282 | 0.010 |
Why?
|
| Random Allocation | 1 | 1990 | 442 | 0.010 |
Why?
|
| In Vitro Techniques | 1 | 1990 | 765 | 0.010 |
Why?
|
| Length of Stay | 1 | 1992 | 780 | 0.000 |
Why?
|
| Hospitalization | 1 | 1992 | 978 | 0.000 |
Why?
|
| South Carolina | 1 | 1992 | 2752 | 0.000 |
Why?
|
| Postoperative Complications | 1 | 1990 | 1615 | 0.000 |
Why?
|